°£¼¶À¯È­ ¼±º° Áø´Ü¹ýÀ¸·Î¼­ÀÇ FIB-4 Á¡¼öÀÇ À¯¿ë¼º
FIB-4 Score as a Useful Screening Test for Diagnosing Liver Fibrosis

Laboratory Medicine and Quality Assurance 2017³â 39±Ç 1È£ p.16 ~ p.22

¾È±¤Áø(Ahn Kwang-Jin) - ¿¬¼¼´ëÇб³ ¿øÁÖÀÇ°ú´ëÇÐ Áø´Ü°Ë»çÀÇÇб³½Ç
±èÁÖ¿ø(Kim Ju-Won) - ¿¬¼¼´ëÇб³ ¿øÁÖÀÇ°ú´ëÇÐ Áø´Ü°Ë»çÀÇÇб³½Ç
±èÀ±Á¤(Kim Yoon-Jung) - ¿¬¼¼´ëÇб³ ¿øÁÖÀÇ°ú´ëÇÐ Áø´Ü°Ë»çÀÇÇб³½Ç
¾î¿µ(Uh Young) - ¿¬¼¼´ëÇб³ ¿øÁÖÀÇ°ú´ëÇÐ Áø´Ü°Ë»çÀÇÇб³½Ç
À±°©ÁØ(Yoon Kap-Jun) - ¿¬¼¼´ëÇб³ ¿øÁÖÀÇ°ú´ëÇÐ Áø´Ü°Ë»çÀÇÇб³½Ç

Abstract

¹è°æ: °£ »ý°ËÀÌ °£ ¼¶À¯È­ÀÇ Ç¥ÁØ Áø´Ü¹ýÀÌÁö¸¸ ħ½ÀÀû ¹æ¹ý¿¡ µû¸¥ ÇÕº´ÁõÀÇ À§ÇèÀÌ »ó´ëÀûÀ¸·Î ³ô´Ù. ºñħ½ÀÀû ¹æ¹ýÀ¸·Î °£¼¶À¯È­½ºÄµÀÌ µµÀԵǾúÀ¸³ª °¡°ÝÀÌ ºñ½Î°í ȯÀÚÀÇ ½Åü»óÅ¿¡ ¿µÇâÀ» ¹Þ´Â´Ù. ÀÌ¿¡ FIB-4 Á¡¼ö´Â ºñħ½ÀÀû °è»ê½ÄÀ¸·Î °£ ¼¶À¯È­ Á¤µµ¸¦ ¿¹ÃøÇÑ´Ù. º» ¿¬±¸´Â °£ ¼¶À¯È­ ´Ü°è ¿¹Ãø¿¡ ÀÖ¾î FIB-4 Á¡¼öÀÇ À¯¿ë¼ºÀ» Æò°¡ÇÏ°íÀÚ ÇÏ¿´´Ù.

¹æ¹ý: ³ªÀÌ, Áø´Ü¸í, °£Åº¼ºµµ, ¾Æ½ºÆĸ£Å×ÀÌÆ®¾Æ¹Ì³ëÀü´Þ-È¿¼Ò(aspartate aminotransferase, AST), ¶ó´Ñ¾Æ¹Ì³ëÀü´ÞÈ¿¼Ò(alanine aminotransferase, ALT), Ç÷¼ÒÆÇ ¼ö¸¦ ÄÚµåÈ­ÇÏ¿© Àǹ«ÀڷḦ ÃßÃâÇÏ¿´À¸¸ç ÃÖÁ¾ÀûÀ¸·Î 282¸íÀÇ È¯ÀÚ °á°ú¸¦ ºÐ¼®ÇÏ¿´´Ù. °£ ź¼ºµµ´Â µÎ ¿¬±¸(Foucher µî, Mueller µî)ÀÇ ºÐ·ù±âÁØ¿¡ µû¶ó °¢°¢ ¼¶À¯È­ µî±ÞÀ» ³ª´©¾ú´Ù. FIB-4 Á¡¼ö´Â ³ªÀÌ(³â)¡¿AST/(Ç÷¼ÒÆÇ ¼ö [109/L]¡¿(ALT)1/2)·Î °è»êÇÏ°í °£¼¶À¯È­½ºÄµ °á°ú¸¦ ¹ÙÅÁÀ¸·Î »ó´ë¼öÇà´É°î¼±(relative operating characteristic curve, ROC curve)À» ±×¸®°í °î¼±¾Æ·¡¸éÀû(area under the ROC curve, AUC)À» ÀÌ¿ëÇÏ¿© °áÁ¤Á¡À» È®ÀÎÇÏ¿´´Ù.

°á°ú: µÎ ºÐ·ù±âÁØÀÌ °øÅëÀûÀ¸·Î Á¤»ó°ú ÁøÇàµÈ °£ ¼¶À¯È­¸¦ ³ª´©´Â FIB-4 °áÁ¤Á¡¿¡¼­ AUC°¡ °¡Àå ÄÇ´Ù. ƯÈ÷ Mueller µîÀÇ ±âÁØÀ» ¹ÙÅÁÀ¸·Î ÇÑ FIB-4 Á¡¼ö°¡ 2.07ÀÏ ¶§ °¡Àå Å« AUC (0.837)¿Í ±³Â÷ºñ(2.741)¸¦ º¸¿´À¸¸ç À̶§ÀÇ ¹Î°¨µµ´Â 78.3%, ƯÀ̵µ´Â 76.5%¿´´Ù.

°á·Ð: º» °Ë»ç½Ç¿¡¼­ÀÇ FIB-4 Á¡¼ö´Â °áÁ¤Á¡À» 2.07·Î ÇßÀ» ¶§ ¸¸¼º°£ÁúȯÀÇ ¼¶À¯È­ ÁøÇàÀ» ¼±º°ÇÏ´Â µ¥ À¯¿ëÇÏ¿´´Ù. °¢ °Ë»ç½Ç¿¡¼­´Â ȯÀÚ Æ¯¼ºÀÌ º´¿ø¸¶´Ù ´Ù¸£¹Ç·Î ÀÚüÀûÀÎ FIB-4 °áÁ¤Á¡À» ¼³Á¤ÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
Background: Liver biopsy is the gold standard for assessing liver fibrosis; however, it has a relatively high risk of resulting in complications. Although a non-invasive method (i.e., transient elastography?fibroscan) was introduced, it is expensive and is dependent on the patient¡¯s status. Thus, the FIB-4 score, a non-invasive formula, has been used to predict the degree of liver fibrosis. The aim of this study was to evaluate the usefulness of the FIB-4 score in predicting stages of liver fibrosis.

Methods: We analysed the age, diagnosis, and liver stiffness of 282 patients by measuring the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as well as their platelet count. Liver elasticity was evaluated by two classification criteria (Foucher et al. and Mueller et al.). The FIB-4 score was calculated using the formula: age¡¿AST/(platelet count¡¿ALT1/2). The cut-off value of the FIB-4 score was determined according to the area under the relative operating characteristic curve (AUC) based on liver elasticity.

Results: The FIB-4 cut-off values, as determined using two different criteria, have the highest AUC, thereby indicating a robust ability to distinguish between healthy liver tissue and the presence of any liver fibrosis. The FIB-4 score with a cut-off value of 2.07, as determined by Mueller et al., had the highest AUC (0.837) and odds ratio (2.741) with a sensitivity of 78.3% and a specificity of 76.5%.

Conclusions: An FIB-4 score of 2.07 is a cut-off value that is useful in detecting fibrotic progression in chronic liver disease in our laboratory. Each laboratory should determine an appropriate FIB-4 cut-off value that is relative to the particular characteristics of their patient population.

Å°¿öµå

FIB-4 score, Screening, Liver fibrosis
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
An FIB-4 score of 2.07 is a cut-off value that is useful in detecting fibrotic progression in chronic liver disease.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå